Literature DB >> 10796922

Retroperitoneal metastases in testicular cancer: role of CT measurements of residual masses in decision making for resection after chemotherapy.

E W Steyerberg1, H J Keizer, D T Sleijfer, S D Fossâ, D F Bajorin, A Gerl, R de Wit, W J Kirkels, H S Koops, J D Habbema.   

Abstract

PURPOSE: To determine the relative importance of computed tomographic (CT) measurements for the prediction of histologic findings in residual masses in patients with nonseminomatous testicular cancer.
MATERIALS AND METHODS: Measurements of the maximum transverse size of retroperitoneal metastases before and after chemotherapy were available in 641 patients who underwent resection after chemotherapy while their levels of tumor markers were normal. Radiologic measurements of mass size and clinical characteristics (histologic findings in primary tumor and levels of alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase before chemotherapy) were related to histologic findings in the residual mass with logistic regression analysis.
RESULTS: At resection, 302 patients had benign tissue, and 339 had residual tumor (mature teratomas or cancer). Tumor was more frequent in larger masses after chemotherapy but was unrelated to mass size before chemotherapy. Inclusion of the reduction in size significantly improved the logistic regression model, which included mass size after chemotherapy. This model was further improved with the addition of clinical characteristics. Areas under the receiver operating characteristic curves increased from 0.74 to 0.77 and 0.83 with these models.
CONCLUSION: A small retroperitoneal mass after chemotherapy is an important predictor of benign histologic findings in residual masses in patients with nonseminomatous testicular cancer. However, better predictions can be made when the reduction in size and clinical characteristics are considered as well. Decisions regarding resection should be based on the combination of these characteristics rather than on only mass size after chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10796922     DOI: 10.1148/radiology.215.2.r00ma02437

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  6 in total

1.  The Road Ahead for Circulating microRNAs in Diagnosis and Management of Testicular Germ Cell Tumors.

Authors:  John T Lafin; Matthew J Murray; Nicholas Coleman; A Lindsay Frazier; James F Amatruda; Aditya Bagrodia
Journal:  Mol Diagn Ther       Date:  2021-04-24       Impact factor: 4.074

Review 2.  Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases.

Authors:  Gregory A Joice; Steven P Rowe; Michael A Gorin; Phillip M Pierorazio
Journal:  Curr Urol Rep       Date:  2018-11-09       Impact factor: 3.092

3.  Management of residual mass in nonseminomatous germ cell tumors following chemotherapy.

Authors:  Siamak Daneshmand; Hooman Djaladat; Craig Nichols
Journal:  Ther Adv Urol       Date:  2011-08

4.  The combination of microRNA-371a-3p and 375-5p can distinguish viable germ cell tumor and teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens.

Authors:  Lara Kremer; Melanie von Brandenstein; Maike Wittersheim; Barbara Koeditz; Pia Paffenholz; Martin Hellmich; David Pfister; Axel Heidenreich; Tim Nestler
Journal:  Transl Androl Urol       Date:  2021-04

5.  A meta-analysis of clinicopathologic features that predict necrosis or fibrosis at post-chemotherapy retroperitoneal lymph node dissection in individuals receiving treatment for non-seminoma germ cell tumours.

Authors:  Ciara Conduit; Wei Hong; Felicity Martin; Benjamin Thomas; Nathan Lawrentschuk; Jeremy Goad; Peter Grimison; Nariman Ahmadi; Ben Tran; Jeremy Lewin
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

6.  Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Testicular Cancer: A Single Center Experiences.

Authors:  Mohamadreza Nowroozi; Mohsen Ayati; Amir Arbab; Hassan Jamshidian; Hamidreza Ghorbani; Hassan Niroomand; Mohsen Taheri Mahmoodi; Erfan Amini; Sohrab Salehi; Hamid Hakima; Farid Fazeli; Saeid Haghdani; Alireza Ghadian
Journal:  Nephrourol Mon       Date:  2015-09-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.